Bill Nye on Genetic Testing, Awareness, and the Future of Friedreich Ataxia Care

Friedreich ataxia (FA) is a rare, inherited neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, and multisystem involvement, driven by GAA trinucleotide repeat expansions in the FXN gene. Although advances in genetic testing have improved diagnostic precision, FA remains frequently underrecognized or misdiagnosed due to overlapping features with other neurologic conditions, reinforcing the importance of early identification and clinical awareness.

At the 2026 American Academy of Neurology (AAN) Annual Meeting, a unique educational session brought together science communicator Bill Nye, neurologist Dr. Kuo, and a patient-researcher living with FA to examine real-world case studies and explore disease recognition, progression, and emerging therapeutic approaches. The session aimed to bridge gaps between scientific understanding, clinical practice, and patient experience, while highlighting the evolving landscape of FA care, including the emergence of disease-modifying therapies and gene-targeted strategies.

Following the meeting, NeurologyLive^® spoke with Nye to gain his perspective on the importance of awareness, the role of genetic testing, and the responsibility of clinicians and scientists in communicating complex neurologic diseases. In this Q&A, Nye reflects on the historical challenges of diagnosing FA, the growing momentum in research, and the opportunities to engage future generations in tackling rare neurologic disorders.

NeurologyLive: For clinicians who may be less familiar, can you provide background on Friedreich ataxia and why this disease is personally meaningful to you?

Bill Nye: My family has a different but related form of ataxia, but what we have in common—Friedreich ataxia and spinal cerebellar ataxia—are caused by repeats in genes. Friedreich is GAA, guanine, adenine, adenine, and you have to have two parents come together who have this recessive gene at the wrong time.

This was described by Nicholas Friedreich in the 1860s, and this is before Darwin and Wallace were even describing evolution. None of them knew there was DNA, let alone GAA repeats. So, it’s an exciting time. What we want to do is raise awareness of ataxia, especially for people who diagnose these things—this would be your audience, I imagine.

It’s been misdiagnosed for centuries, I suppose, because it has symptoms in common with other neurologic disorders. The advantage of diagnosing it early is that you can do something about it, albeit a limited number of things. Speaking for my family, there are new drugs being produced, molecules being created, that definitely help people like my cousins and immediate family.

It was an honor to be included. And the example I’ve been giving everybody these days is—I’m watching cable news the way people my age do—and here comes a commercial for dog food, refrigerated dog food that supposedly gives your dog superpowers. I’m exaggerating, but they mentioned the word “ataxia.” It helps your dog’s ataxia. I mean, two years ago, nobody was throwing that word around, especially in a television commercial. We’ve raised awareness. Check that box.

What challenges did you encounter when communicating complex neurologic concepts to a clinician audience at AAN?

Well, people are more alike than they are different. In my experience, neurologists and clinicians can understand the idea. The big thing at AAN was to get people aware that Friedreich ataxia can mimic other neurologic diseases, and it’s not in anybody’s best interest to misidentify it. We want you to sort it out and identify it.

In the case of Friedreich ataxia, you’ve got to use discipline in vocabulary. I remember a guy there talking about “different therapeutic modalities.” Those are both English words, but it’s not the way most people who have Friedreich ataxia—or whose family has it—would talk about it. Maybe they do after a few years of reading the brochures, but I remember hearing that phrase and thinking, man, this is a niche. This is a small group of people who would turn that phrase.

How do you view the role of genetic testing in improving early diagnosis and potentially preventing Friedreich ataxia?

Well, if I can project—as we say in psychology, or maybe psychiatry—if I can project, if two people who are considering getting married and having babies could get tested and identify this potential problem, it seems to me that, at least in the developed world, we could eliminate it in just one generation.

If both people have this genetic disposition, then you could either decide not to have kids or select embryos that do not have this condition. It seems reasonable to me. That would be remarkable.

You think about evolution—the reason this condition has persisted since the dawn of humankind, it’s because it’s recessive. You have to have the coincidence of two people coming together with the gene, and then it expresses itself. So, it’s really an amazing evolutionary story, as well as a clinical story, and even a story about the future of humankind.

It’s an exciting time, and this is possible because of genetic testing and the discovery of the GAA repeat.

In today’s environment of widespread misinformation, what responsibility do clinicians and scientists have in communicating evidence-based information?

Well, we want the world to embrace the facts. Wouldn’t that be nice? But humankind has a long history of not quite embracing facts and instead embracing stories that are appealing but may not be factual.

What we want to do, if we could do one thing, is develop people so they have critical thinking skills. That would be the greatest thing—the habit of mind where you evaluate evidence and don’t necessarily take everyone’s word for it. On the other hand, you still respect expertise.

Doing your own research online has proven to be very troublesome for a lot of people. But aside from that, do clinicians have a responsibility? I don’t know—if you want to enjoy your life, I guess so. When you’re in love, you want to tell the world. And I presume people who go into neurology do it because they want people to know how exciting it is—making discoveries about brains, nerves, genes, and ataxia.

What are your current goals and priorities, particularly related to science and healthcare?

Well, we like to talk about the Constitution—Article One, Section Eight—which outlines the responsibilities of the legislative branch. In there is the phrase “to promote the progress of science.” The word science is in the Constitution.

Right now, I’m very interested in getting legislators elected who will promote the progress of science rather than not. That’s of great interest to me.

My parents were both World War II veterans. My dad’s side of the family had spinal cerebellar ataxia, and it was passed on to my siblings and cousins. We want people to be aware of it and to address it through science. Now more than ever, as the old saying goes.

What opportunities exist to better engage the next generation of clinicians and researchers in rare neurologic diseases like Friedreich ataxia?

Well, they should visit your website and turn it up loud. I mean, isn’t that the answer? To get out as much information as we can.

Just the fact that the word “ataxia” shows up in commercials is progress. People are becoming aware of it. In the same way people talk about multiple sclerosis as MS or ALS as Lou Gehrig’s disease, we want awareness.

I don’t want anybody to have ataxia, but I want people to know the word. The longest journey begins with a single step—kind of a pun in this case—but we want to get the word out so we can create a cadre of the next generation of researchers who might go into this field and solve the problem.

Just that there are handicapped parking spaces, and people respect them, is evidence of progress. Society has moved forward. Treatments have been developed for many conditions, and I’m hopeful that treatments will be developed for Friedreich ataxia and related disorders.

So let’s go—young people, go into this field and change the world.

Transcript was edited for clarity. Click here for more AAN 2026 coverage.